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Abstract
Introduction: To date only two studies have evaluated anemia status in acute intracerebral hemorrhage (ICH)
reporting that on admission anemia (OAA) was associated with larger hematoma volume, and lower hemoglobin
levels during hospital stay, which related to poorer outcome. The question remains whether anemia influences
outcome through related volume-effects or itself has an independent impact?
Methods: This single-center investigation included 435 consecutive patients with spontaneous ICH admitted to the
Department of Neurology over five years. Functional short- and long-term outcome (3 months and 1 year) were
analyzed for anemia status. Multivariate logistic and graphical regression analyses were calculated for associations
of anemia and to determine independent effects on functional outcome. It was decided to perform a separate
analysis for patients with ICH-volume <30cm3 (minor-volume-ICH).
Results: Overall short-term-outcome was worse in anemic patients (mRS[4-6] OAA = 93.3% vs. non-OAA = 61.2%, P
< 0.01), and there was a further shift towards an increased long-term mortality (P = 0.02). The probability of
unfavorable long-term-outcome (mRS[4-6]) in OAA was elevated 7-fold (OR:7.5; P < 0.01). Receiver operating
characteristics curve (ROC) analysis revealed a positive but poor association of ICH-volume and anemia (AUC =
0.67) suggesting volume-undriven outcome-effects of anemia (AUC = 0.75). Multivariate regression analyses
revealed that anemia, besides established parameters, has the strongest relation to unfavorable outcome (OR:3.0; P
< 0.01). This is even more pronounced in minor-volume-ICH (OR:5.6; P < 0.01).
Conclusions: Anemia seems to be a previously unrecognized significant predictor of unfavorable functional
outcome with independent effects beyond its association with larger hemorrhage volumes. The recognition of
anemia and its treatment may possibly influence outcome after ICH and as such prospective interventional studies
are warranted.
Keywords: Intracerebral haemorrhage, Spontaneous ICH, On admission anemia, Unfavorable outcome, Outcome
predictor
Introduction
Anemia is a common finding among intensive care
patients, with 95% being anemic by day 3 and up to
50% receiving red blood cell (RBC) transfusions during
their stay [1]. For neurocritical care patients, most
research has been conducted for traumatic brain injury
and subarachnoid hemorrhage, documenting associa-
tions for lower Hb-levels with poorer outcome, but
large randomized controlled trials (RCT) are missing
[2-4]. Despite existing evidence in general intensive care
the appropriate treatment strategy for these brain-
injured patients still needs to be elucidated [2,5].
For intracerebral hemorrhage (ICH) only three studies
are available that analyzed anemia, though including
heterogeneous patient populations, for example, ICH
related to oral anticoagulants. Diedler and colleagues
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found an association of a nadir hemoglobin level during
hospital stay with functional outcome in supratentorial
ICH [6]. Kumar and co-workers identified on-admission
anemia (OAA) to be independently associated with
increased hemorrhage volumes and multivariate analysis
suggested that anemia might have effects on outcome
not related to ICH volume [7]. Another recent study
investigated the influence of RBC transfusions during
acute ICH treatment and reported improved survival
rates at 30 days though transfusion regimes have not
been investigated [8].
It remains unclear whether anemia is a marker for mori-
bund patients with a poor prognosis, or if anemia directly
leads to increased hemorrhage volumes impacting
outcome [6,7]. Given this controversy, the present study
sought to investigate the impact of anemia on functional
outcome in solely spontaneous ICH patients. Based on the
strong association of ICH volume and outcome, and in
light of large hemostatic and blood pressure lowering trials
failing to influence clinical endpoints after enrolling
patients with ICH volumes up to 60 cm3 [9,10], defining
rather tighter volume cutoffs - as done in the ongoing
CLEAR-IVH trial (ICH volume <30 cm3 [11]) - appears
reasonable. As anemia represents an easily treatable medi-
cal condition, which, if compensated, may possibly influ-
ence functional outcome, we performed a sub-analysis in
‘minor-volume’ ICH (that is, <30 cm3) to minimize
volume-based outcome effects and to evaluate the
relevance of anemia in this special cohort.
Materials and methods
Patient selection
The study was performed in accordance with ethical stan-
dards and was approved by the ethics committee of the
Friedrich-Alexander University Erlangen-Nuremberg,
Germany. Informed consent was obtained from all
patients or legal representatives. All consecutive patients
with spontaneous ICH admitted to the Department of
Neurology over a 5-year period (2006 to 2010) were retro-
spectively analyzed from our prospective institutional
database. By definition, we excluded secondary ICH; that
is, ICH related to oral anticoagulant therapy, trauma,
tumor, arteriovenous malformations, central venous
thrombosis, subarachnoid hemorrhage, or ICH after acute
thrombolysis or coagulopathy (platelet counts <50.000/μL;
INR >1.4). Altogether, 464 spontaneous ICH patients were
identified from our database, 29 patients were lost to
follow-up or refused consent. Hence, 435 (93.7%) patients
of central European descent remained for final analysis.
We a priori decided to perform a separate analysis for
those patients of our cohort who showed a parenchymal
ICH volume <30 cm3 (n = 267; in the following referred to
as ‘minor-volume’ ICH patients).
Parameter acquisition
In-hospital parameters (Glasgow Coma Scale (GCS),
National Institute of Health Stroke Scale (NIHSS)), ICH
score, blood pressure, mechanical ventilation, length of
stay, external ventricular drainage (EVD) for occlusive
hydrocephalus [12], diagnosis of pneumonia, urinary tract
infection, and sepsis according to established criteria
[13-15] were obtained by reviewing the patient’s medical
charts and institutional databases. Initial laboratory
parameters were retrieved from our laboratory database.
Anemia was defined according to WHO definitions (Hb
<12 mg/dl for women, Hb <13 mg/dl for men) [5,16].
Further, OAA will be referred to as anemia within the text
and for reasons of brevity as OAA in tables and figures.
Patient characteristics (history of ischemic or hemorrha-
gic stroke, cardiovascular events as myocardial infarction),
use of nicotine, alcohol abuse, diagnosis of arterial
hypertension, diabetes mellitus, and hypercholesterolemia
- according to established criteria [17-19] - were evaluated
by a standardized mailed questionnaire. A semi-quantita-
tive phone interview with patients or their closest relatives
was conducted whenever this questionnaire did not return
within 4 weeks. In cases of insufficient data retrieval (n =
39 patients; no correlation with neurological outcome),
primary care physicians were contacted by telephone
interview. The 435 investigated patients responded in
73.8% (n = 321) by questionnaires and 26.2% (n = 114) by
telephone interviews. Two physicians (JBK, SG) trained
and certified for data collection on disability and quality of
life performed these interviews.
Outcome measures
Mortality and functional outcome 90 days (short-term
outcome) and 1 year (long-term outcome) after disease
onset were obtained as described above and evaluated
using the modified Rankin scale (mRS) [20]. A favorable
outcome was defined as a mRS between 0 and 3, an unfa-
vorable outcome as a mRS of 4 to 6. Moreover, a ‘shift’
from short- to long-term outcome was analyzed separately
for the entire cohort as well as for minor-volume ICH
patients.
Imaging
Diagnosis was made either by computed tomography (SIE-
MENS Somatom Volume Zoom, Germany) or magnetic
resonance imaging (SIEMENS Sonata, 1.5 Tesla, Ger-
many). Two neuroradiologists (HL and SK) blinded to
clinical data reviewed the scans randomized and indepen-
dently. For discrepancies a second consensus analysis was
made. Hematoma growth (volume >33% [21]) was deter-
mined upon follow-up imaging which was performed
within 24 ± 6 h. Parenchymal ICH volume was calculated
by the formula of ellipsoids (ABC/2) [22] and imaging
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modalities were compared using a validated conversion
model [23]. IVH was documented and scored by Graeb
score summation (GS) [24], and midline shift was mea-
sured in mm.
Statistical analysis
Statistical analysis was performed with SPSS 19.0 [25].
The significance level was set at a = 0.05. Statistical
tests were two-sided. The Kolmogorov-Smirnov test was
applied to determine distribution of the data. Latter are
presented as mean ± SD (compared using the student
T-test), or as median and interquartile range (IQR)
(compared using the Mann-Whitney U-test), as appro-
priate. The Pearson-c2 and the Fisher’s exact tests were
used to compare frequency distributions of categorized
variables between anemic and non-anemic patients. The
correlation of anemia with hemorrhage volume and
functional outcome was graphically analyzed by the
receiver operating characteristics curve (ROC) [26]. The
influence of ICH volume on functional outcome (OAA
versus non-OAA) was analyzed by graphical regression
analysis, the locally weighted scatterplot smoothing
(LOWESS) with a = 0.25-0.5. A sub-analysis for minor-
volume ICH (ICH volume <30 cm3) patients was under-
taken to discriminate the effects of anemia from the
overwhelming impact of ICH volume. For prediction of
unfavorable long-term outcome (mRS = 4-6) two step-
wise forward inclusion multivariate logistic regression
models were calculated, one for the entire cohort and
one for minor-volume ICH patients. For both models all
investigated parameters were first tested univariately.
Consecutively, parameters reaching a statistical trend in
univariate analysis (that is, P < 0.1) were included into
the multivariate models.
Results
Anemic patients have larger baseline volumes and poorer
neurological status
All evaluated parameters dichotomized for OAA versus
non-OAA are given in Table 1. Overall, 24.1% of patients
were anemic on admission and as key findings showed sig-
nificantly larger ICH volumes (48.6 cm3 versus 15.0 cm3; P
< 0.01) and neurological status was considerably poorer (P
< 0.01). There were no co-morbidities that revealed a sig-
nificant association with anemia.
Outcome and shift from short- to long-term outcome is
worse in anemic patients
Figure 1 shows the mRS distribution at 90 days and the
long-term outcome-shift (at 1 year) among the analyzed
patients. In comparison both short- and long-term out-
come were significantly poorer in anemic patients (mRS: 4-
6 (90 days): OAA = 93.3% versus non-OAA = 61.2%, P <
0.01; mRS: 4-6 (1 year): OAA = 89.5% versus non-OAA =
53.3%, P < 0.01) For both groups the proportion of patients
showing a favorable long-term outcome increased from 3
months to 1 year. However, the probability of a favorable
long-term outcome shift was significant only in non-ane-
mic patients (chance for shift to favorable outcome in non-
OAA: OR: 1.5; CI (1.05-2.07); P = 0.02 versus OR: 1.7; CI
(0.61-4.69); P = 0.31 in OAA). On the other hand, for ane-
mic patients the probability of a 1-year mortality was
higher (OR: 2.4; CI (1.12-5.1); P = 0.02) and translated to a
more than seven-fold increased risk for an unfavorable
long-term outcome (OR: 7.5; CI (3.87-14.48); P < 0.01).
Association of hematoma volume with outcome is less
accurate and less relevant in anemia
The reported difference in overall outcome between
anemic and non-anemic patients may be theoretically
attributed to the different baseline hemorrhage volumes,
and corresponding GCS and NIHSS scores, respectively.
Therefore, a graphical analysis was performed to analyze
the accuracy of the associations for anemia with larger
hematoma volumes and functional outcome. Figure 2A
shows the ROC curve for the associations of anemia
with ICH volume and functional outcome. Anemia
revealed a positive but poorer association with larger
hemorrhage volumes (AUC = 0.67), whereas the associa-
tion with functional outcome was positive and more
accurate for all spontaneous ICH patients in our study
(AUC = 0.75; CI (0.70-0.80); P < 0.01).
To investigate the influence of ICH volume on func-
tional outcome for patients with and without anemia, a
graphical regression analysis is shown in Figure 2B. The
inclination of the curves demonstrates the influence of
hematoma volume on outcome, being the stronger the
steeper. The OAA curve showed a relatively flat constant
slope, regardless of increasing volumes, demonstrating
marginal effects of ICH volume on functional outcome.
The inclination of the non-OAA curve was considerably
steeper, especially for smaller ICH volumes up to approxi-
mately 30 cm3 reflecting a stronger influence of hematoma
volume on outcome in these ‘minor-volume’ non-anemic
patients. Thereafter, the influence of volume on outcome
also decreased in non-anemic patients, revealing a certain
volume ‘cutoff’ after which outcome was likely to be poor
in any case.
Worse outcome in minor-volume ICH patients with
anemia despite similar characteristics
In light of the previous investigation proposing anemia-
related outcome effects beyond its association with hema-
toma volume [7], a sub-analysis of minor-volume ICH
patients was performed to minimize volume-related effects
on outcome. Of the 267 patients with an ICH volume
<30 cm3 anemia was present in 42 patients (15.7%).
All parameters (as analyzed in Table 1) were tested and
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Table 1 Demographic-, baseline,-, neuroradiological-, laboratory, treatment characteristics for all ICH patients with
OAA versus non-OAA.
Spontaneous ICH (n = 435) OAA (n = 105) Ø OAA (n = 330) P value
Agea (years) 71.4 (± 12.4) 69.1 (± 11.9) 0.09
Genderb (women) 49 (46.7%) 147 (44.5%) 0.70
Prior medical history
Pre-mRSc 1 (0-3) 1 (0-3) 0.14
Hypertensionb 80 (76.2%) 261 (79.1%) 0.34
Diabetesb 25 (23.8%) 83 (25.2%) 0.45
Hypercholesterolemiab 26 (24.8%) 94 (28.5%) 0.27
Ischemic strokeb 28 (26.7%) 63 (19.1%) 0.10
Hemorrhagic strokeb 9 (8.6%) 33 (10.0%) 0.40
Cardiac eventb 14 (13.3%) 52 (15.8%) 0.33
Alcohol abuseb 21 (19.6%) 60 (15.3%) 0.39
Smokingb 30 (28.6%) 111 (33.6%) 0.20
Antiplatelet useb 43 (40.9%) 118 (35.8%) 0.38
On admission status
NIH-Stroke Scalec 22 (15-32) 14 (5-24) <0.01
Glasgow Coma Scalec 7 (3-13) 13 (7-15) <0.01
ICH-Scorec 3 (2-4) 1 (0-3) <0.01
MAPa (mmHg) 113 (± 27.6) 116 (± 26.7) 0.51
Neuroradiological data
Location; basalgangliab 54 (51.4%) 158 (47.9%) 0.64
Location; lobarb 44 (41.9%) 131 (39.9%) 0.69
Location; brainstemb 5 (4.8%) 21 (6.4%) 0.55
Location; cerebellarb 2 (1.9%) 20 (6.1%) 0.12
ICH volume (cm3) 48.6 (12.1-82.2) 15.0 (4.8-40.6) <0.01
IVHb 74 (70.5%) 176 (53.3%) <0.01^
Graeb Scorec 4 (0-8) 1 (0-4) <0.01
Hematoma growthb 16 (15.2%) 38 (11.5%) 0.31
Midline shiftc (mm) 6 (2-10) 0 (0-5) <0.01
Laboratory values on admission
Hemoglobina (mmol/L) 6.93 (± 0.81) 8.97 (± 0.87) <0.01
Hematocrita 0.33 (± 0.04) 0.41 (± 0.04) <0.01
Leucocytesc (10^9/L) 8.8 (6.3-12.3) 9.3 (7.2-11.7) 0.34
Thrombocytesc (10^9/L) 235 (153-299) 228 (193-284) 0.44
International Normalized Ratioa 1.05 (± 0.18) 1.01 (± 0.06) 0.07
Partial thromboplastin timea (s) 28.4 (± 4.3) 28.7 (± 3.7) 0.62
Creatininec (μmol/L) 84.9 (64.5-102.6) 81.3 (69.0-97.3) 0.60
C-reactive proteinc (nmol/L) 47.6 (9.5-127.6) 29.5 (10.5-76.2) 0.18
Glucosec (mmol/L) 7.49 (6.52-10.07) 7.38 (6.05-9.05) 0.11
In-hospital measures
Mechanical ventilationb 55 (52.4%) 132 (40.0%) 0.03d
Duration of ventilationc (days) 12 (2-22) 12 (3-23) 0.33
Pneumoniab 70 (66.7%) 163 (49.4%) <0.01d
Sepsisb 16 (15.2%) 33 (10.0%) 0.14
Urinary tract infectionb 11 (10.5%) 35 (10.6%) 0.99
Extraventricular drainageb 27 (25.7%) 90 (27.3%) 0.75
Length of stayc (days) 10 (3-20) 11 (6-18) 0.11
In hospital mortalityb 42 (40.0%) 60 (18.2%) <0.01
aMean (± SD).
bn (%).
cMedian (IQR; 25th-75th percentile).
dNot sig. after Bonferroni correction.
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the relevant ones shown in Table 2; in particular, the
parameters age, hemorrhage volume, and GCS were not
statistically different among the compared groups. How-
ever, anemic patients appeared to have a tendency towards
an increased rate of hemorrhage growth (P = 0.07).
Despite similar baseline parameters both short- and
long-term outcome were also significantly worse in
patients with anemia as compared to those without
(Figure 3A, mRS: 4-6 (90 days): OAA = 90.5% versus
non-OAA = 47.1%, P < 0.01; mRS: (1 year): OAA = 85.7%
versus non-OAA = 39.6%, P < 0.01). Again for both groups
the proportion of patients showing a favorable long-term
outcome increased from 3 months to 1 year. Though, sta-
tistically not significant, the results were showing the same
trends as for the overall cohort: (1) improvement in non-
anemic; and (2) increased mortality in anemic patients (P =
0.08, P = 0.08). The probability of an unfavorable long-
term outcome was nine-fold increased for anemic patients
(chance of mRS 4-6 OR: 9.2; CI (3.71-22.66); P < 0.01).
Figure 3B compares the effects of hematoma volume -
stratified volume intervals (10 cm3) - on long-term func-
tional outcome. There was a significant association of
increasing hemorrhage volume and poor outcome in non-
anemic patients, whereas anemic patients did not show
this association in minor-volume ICH.
Anemia is an independent predictor of unfavorable long-
term outcome in ICH
In multivariate regression modelling the parameter anemia
showed the strongest significant relation to long-term
Figure 1 Dichotomized analysis of the mRS distribution at 90 days and 1 year for non-OAA and OAA patients. The dashed line
indicates, within the mRS = 6 group, the proportion of patients who died in the hospital (DIH). The thickness of arrows indicates the
proportional shift from short- to long-term outcome within the mRS groups.
Figure 2 (A) Receiver operating characteristics curve for the association of OAA with ICH volume and outcome. (B) Graphical regression
analysis; LOWESS graph (a = 0.25-0.5, tension = 66), evaluating the influence of ICH volume on outcome for OAA- and non-OAA patients. Note,
that in non-OAA patients hematoma volume is of greater relevance to outcome (especially for volumes < 30 cm3) than in OAA-patients.
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outcome, along with established parameters such as
age, hemorrhage volume, GCS, IVH, and presence of
hemorrhage growth (Table 3A; OR: 3.0; CI (1.31-7.06); P <
0.01). Focussing on patients with minor-volume ICH, mul-
tivariate regression analysis revealed an even stronger
significant association of anemia with poor outcome
(Table 3B; OR: 5.6; CI (1.84-16.85); P < 0.01). Interestingly,
in minor-volume ICH patients parameters such as hemor-
rhage volume and ventricular involvement did not hold
significance when adjusted for anemia.
Discussion
In the present study we analyzed associations of anemia
with hemorrhage volume and its impact on functional out-
come in patients with spontaneous ICH. Overall, the pre-
sence of anemia is high and affects almost one-quarter of
these patients. Anemia was associated with larger baseline
hemorrhage volumes and worse outcome as compared to
patients without. However, anemia revealed independent
effects on functional outcome beyond the - at first glance
trivial - association with hematoma volume. Especially, in
patients with minor-volume ICH with an increased likeli-
hood of favorable functional recovery, anemia impacted
outcome independently and to a larger degree than estab-
lished parameters. Several aspects deserve attention.
Prevalence and general aspects
The prevalence of anemia in the community-dwelling
population of patients aged >65 years is >10%, increases
profoundly with age and is often multifactorial [16]. Nutri-
tional deficiency anemia, anemia of inflammation, and
anemia of unknown causes are the most frequent
sub-types [16]. Anemia, in general, is known through large
population-based studies to contribute to a higher likeli-
hood of an unfavorable outcome and increased mortality
[27-29]. Focussing on ICH patients who are severely
diseased with a high mortality rate and poor prognosis per
se, it seems rational that the hemorrhage itself attracts
much of the medical attention [30]. However, in light of
almost 25% of ICH patients presenting with anemia and
given its independent impact on outcome, as reported
here, it seems necessary to improve recognition and treat-
ment of anemia on stroke and neurocritical care units.
Overall impact of anemia on hemorrhage volume and
outcome
In line with Kumar and colleagues [7], patients with ane-
mia showed an association with larger ICH volumes.
There are several studies that established the influence of
anemia and abnormal coagulation, hemostatic alterations,
and an increased bleeding tendency [31-33]. Our findings
support the necessity to verify this small body of evidence
- corroborating the belief of anemia-associated increased
ICH volumes - by analyses of larger patient cohorts from
RCTs. Moreover, there may be independent effects of
anemia on outcome that act beyond ICH volume estab-
lishing anemia itself as a condition of general morbidity
and increased mortality. Our results for anemic patients
convey less functional recovery and a greater proportion
of patients passing away during the course after ICH.
Therefore, anemia seems to be related to consecutive
clinical detoriation in spite of the generally accepted
improvements that occur over time [34]. The recognition
of anemia has increased across various medical specialties
within the emerging concepts of ageing and frailty.
Anemia may possibly be more than a contributor to
detoriation after ICH and also be relevant to the neurolo-
gical status upon initial presentation [35-38]. Again,
detection and treatment of anemia seems easily doable
and its influence on outcome in ICH needs urgently to
be determined.
Anemia identifies patients at risk for poor outcome in
minor-volume ICH
The relevance of anemia is even more striking in
minor-volume ICH patients. Despite similar baseline
Table 2 Demographic-, baseline,-, neuroradiological-,
laboratory, treatment characteristics for minor-volume
ICH patients with OAA versus non-OAA.
Minor-volume ICH (n = 267) OAA (n =
42)




Agea (years) 71.8 (± 11.4) 69.1 (± 12.0) 0.06
On admission status
Glasgow Coma Scaleb 12 (3-15) 13 (3-15) 0.11
ICH-Scoreb 2 (1-3) 1 (0-2) 0.01c




ICH volumeb (cm3) 8.8 (3.5-14.9) 7.4 (2.9-15.6) 0.64
IVHd 23 (54.8%) 105 (46.7%) 0.33
Graeb Scoreb 1 (0-4) 0 (0-3) 0.30
Hematoma growthd 9 (21.4%) 25 (11.1%) 0.07
Midline shiftb (mm) 0 (0-3) 0 (0-2) 0.10
Laboratory values on admission
International Normalized
Ratioa
1.05 (± 0.09) 1.04 (± 0.11) 0.49
Partial thromboplastin
timea (s)
29.8 (± 3.8) 28.9 (± 3.6) 0.28
In-hospital measures
Mechanical ventilationd 19 (45.2%) 77 (34.2%) 0.17
Pneumoniad 20 (44.4%) 88 (39.1%) 0.30
In hospital mortalityd 10 (23.8%) 18 (8.0%) 0.05c
aMean (± SD).
bMedian (IQR; 25th-75th percentile).
cNot sig. after Bonferroni correction.
dn (%).
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clinical and radiological characteristics anemia strongly
impacted outcome. Especially, considering the out-
come-shift in anemic patients resulted in a higher
probability of unfavorable long-term outcome. The
only meaningful explanation for the observed outcome
difference is the anemic condition itself. Though, ane-
mia was not as prevalent in minor-volume ICH, as
compared to the entire cohort, focusing on hemoglo-
bin levels upon admission may help identifying high-
risk patients with co-morbidity and increased risk for
hemorrhage growth. Latter as an important predictor
of outcome in ICH [21] which may theoretically be
influenced specifically in anemic patients by hemostatic
drugs [30]. Other detrimental anemia-based mechan-
isms refer to neuronal tissue hypoxia, metabolic dis-
tress, and cell energy dysfunction that possibly lead to
pronounced secondary cerebral injury by a reduced
oxygen carrying capacity. [4,39-41].
Treatment of anemia during acute phase?
In neurocritical care acute treatment strategies using RBC
transfusions and its appropriate thresholds remain contro-
versially debated resulting in widespread practice varia-
tions [2,4,8,42]. Recently, Sheth and colleagues presented a
large retrospective study describing a decreased mortality
for anemic ICH patients who received RBC transfusions
during hospital stay [8], although exact transfusion
regimes have not been investigated. Therefore, in regard
of the existing evidence of conventional transfusion strate-
gies for general ICU patients (TRICC study), a more
liberal transfusion regime has to be very cautiously evalu-
ated in each patient and also balanced against ethical
concerns because of blood product shortage [2,5]. More-
over, disease entities are different in neurocritical care
requiring specific approaches which may not be general-
ized [1,2,4]. For instance, in SAH the value of anemia and
its possible compensation by RBC transfusions has not
Figure 3 (A) Dichotomized analysis of the mRS distribution at 90 days and 1 year for non-OAA and OAA patients with minor-volume ICH.
The dashed line indicates, within the mRS = 6 group, the proportion of patients who already died in the hospital (DIH). The thickness of arrows
indicates the proportional shift from short- to long-term outcome within the mRS groups (B) Association of hematoma volume and outcome in
non-OAA patients and OAA patients. Note, that there is a clear association of hematoma volume and outcome only in non-OAA patients.
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been entirely clarified [2,43]. It is indispensable to investi-
gate the pros and cons of administering RBC transfusions
with its specific thresholds in neurocritical care, especially
in ICH. Only a well-designed prospective interventional
study may resolve the question if compensating lowered
hemoglobin levels affects mortality and functional out-
come. In any case it should be focused on minor-volume
ICH patients with a greater chance of recognizing treat-
ment effects.
Our study has a number of limitations: (1) the retrospec-
tive, single-center design; (2) the mailed questionnaires
may have been answered wrongly with respect to the
time-point of follow-up and validity of mRS estimation
[44]; (3) hematologic investigations for the different etiolo-
gies of anemia have not been applied; (4) the results may
have been biased by the 29 patients lost to follow-up; (5)
although anemia was an independent outcome-predictor,
residual confounding by parameters not investigated as
well as interactions between poorer neurological admis-
sion status and outcome may not be fully excluded; (6)
moreover, ICH itself may hypothetically cause anemia
which however seems unlikely according to available data
[45]; (7) finally, our study descriptively analyzed relations
of anemia and outcome. Given the study design we were
not able to contribute to a better understanding of under-
lying causes, notably a biologically plausible mechanism of
how outcome is influenced by an anemic condition.
Conclusions
Within this observational cohort study, anemia is inde-
pendently associated with unfavorable functional out-
come in ICH beyond its relationship with larger
hemorrhage volumes, the latter being basically less rele-
vant in anemic patients. This also holds true for rather
therapeutically relevant patients with minor-volume ICH
and good chances for recovery. Prospective trials with
precise hematological evaluations and interventions are
warranted to clarify potential treatment options in
patients with anemia and ICH.
Key messages
• Anemia is positively but poorly associated with lar-
ger hemorrhage volumes.
• Anemia is a previously unrecognized independent
predictor of unfavorable functional outcome with an
odds ratio of 3.
• Negative long-term outcome-shift in patients with
anemia; ® seven times more likely to have unfa-
vourable long-term outcome.
• Minor-volume ICH anemia exerted even stronger
independent effects on outcome with an odds ratio
of 5.6.
• Prospective trials with precise hematologic assess-
ment and interventions are warranted in ICH
patients.
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receiver operating characteristics curve; SAH: subarachnoid hemorrhage; TBI:
traumatic brain injury.
Table 3 Multivariate regression models for predictors of unfavorable (mRS = 4-6) functional outcome at 1 year.
Multivariate - parameters Unfavorable outcome Odds ratio (95% CI) P value (P < 0.05)
A) Overall ICH patients
Age 1.102 (1.070-1.136) <0.0001
Volume 1.022 (1.007-1.038) 0.0050
GCS 0.858 (0.788-0.934) 0.0004
IVH (Graeb Score) 1.140 (1.031-1.261) 0.0108
Hematoma growth 2.903 (1.188-7.093) 0.0194
Diagnosis of hypercholesterolemia 0.809 (0.435-1.505) 0.5030
Ventilation 1.030 (0.996-1.064) 0.0807
On admission anemia 3.045 (1.314-7.058) 0.0094
B) Minor-volume ICH patients
Age 1.102 (1.062-1.144) <0.0001
Volume 1.032 (0.990-1.076) 0.1345
GCS 0.755 (0.668-0.854) <0.0001
IVH (Graeb Score) 1.039 (0.920-1.174) 0.5388
Hematoma growth 4.646 (1.561-13.831) 0.0058
Diagnosis of hypercholesterolemia 0.711 (0.334-1.513) 0.3761
Ventilation 1.015 (0.970-1.063) 0.5126
On admission anemia 5.573 (1.843-16.853) 0.0023
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